Brief: Eloxx Pharmaceuticals Announces Initiation Of Phase 2 Clinical Study Evaluating Elx-02 For Treatment Of Alport Syndrome With First Patient Dosed
27/02/2023 22:27
Feb 27 (Reuters) - Eloxx Pharmaceuticals Inc ELOX.O :
* ELOXX PHARMACEUTICALS ANNOUNCES INITIATION OF PHASE 2
CLINICAL
STUDY EVALUATING ELX-02 FOR TREATMENT OF ALPORT SYNDROME WITH
FIRST PATIENT DOSED
* ELOXX PHARMACEUTICALS INC - TOPLINE RESULTS ARE EXPECTED
IN
FIRST HALF OF 2023
Source text for Eikon: ID:nGNX5tx3GC
Further company coverage: ELOX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eloxx Pharmaceuticals
See all newsNASDAQ RESUMED AT 02:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome